ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Clinical trial NCT05650879 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05650879
Sponsor: Enliven Therapeutics
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

HER2 Mutant Non-small Cell Lung Cancer HER2-positive Metastatic Breast Cancer HER2 Gene Mutation HER2 Amplification

Start date: 2023-03-20
Primary completion: 2026-07-01
Enrollment: 198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.